Today: 30 April 2026
Via Transportation stock rises today as VIA trims post-IPO slump in New York trade
31 December 2025
2 mins read

Via Transportation stock rises today as VIA trims post-IPO slump in New York trade

NEW YORK, December 31, 2025, 10:45 ET — Regular session

  • Via Transportation shares rose about 3% to $30.38 in morning trading, after opening at $29.14.
  • The NYSE-listed transit software maker remains roughly a third below its $46 IPO price.
  • Investors are watching for fresh contract wins and the next earnings update after Via’s recent Downtowner acquisition.

Shares of Via Transportation Inc climbed about 3% to $30.38 by late morning on Wednesday, after trading as low as $29.40 and as high as $30.51. About 110,000 shares had changed hands.

The bounce matters because Via is still in the early months of life as a public company, when liquidity and valuation can swing sharply on small shifts in sentiment. Investors are also trying to map a contract-heavy public transit business onto a quarterly earnings calendar.

Via sells software that helps transit agencies and cities run on-demand shuttles and other “microtransit” services — smaller vehicles routed dynamically rather than on fixed schedules — and it went public in September in a U.S. IPO that raised about $493 million at the top of its range. Reuters

The stock’s $46 IPO price has acted as a reference point for investors as the shares have traded well below that level for much of the fourth quarter.

The most recent major catalyst came on December 15, when Via said it completed the acquisition of Downtowner Transportation LLC and its affiliated subsidiaries, a transportation technology company focused on “Destination Cities.” An 8-K filing described the deal as expanding Via’s public transit platform into a segment with different ridership patterns and municipal customers.

In a separate announcement, Via said the Downtowner purchase would broaden its product lineup for cities that need smaller-scale service and routing tools that can be deployed quickly.

The company last reported quarterly results in November, when it posted third-quarter revenue of $110 million and said its platform annual run-rate revenue rose 32% from a year earlier to $439 million. Run-rate revenue is a way companies annualize recent sales to show the current pace of business, but it is not the same as a forecast.

Via has also pointed to partnerships as it expands beyond traditional city bus networks. In September, Via and Alphabet’s Waymo said they struck a deal to support a ride-hailing platform for Waymo’s autonomous vehicles, Reuters reported.

Wednesday’s move leaves investors with familiar questions that have dogged many 2025 IPOs: how quickly can revenue growth turn into cash flow, and how durable is demand if municipal budgets tighten. For Via, that debate is sharpened by the long sales cycles and stop-start timing of public-sector contracts.

Traders are likely to focus on signs of contract momentum — new agency wins, renewals and expansions — because those items can drive the top line faster than cost-cutting. They will also watch whether Via can improve profitability as it integrates Downtowner and rolls out products across more cities.

Another swing factor is execution risk. Integrations can add near-term costs, and the company’s ability to cross-sell and retain customers will determine whether an acquisition adds durable revenue or just a one-time boost.

Stock Market Today

  • Biogen Shares Rise 6% After Q1 Earnings Beat Despite Guidance Cut
    April 29, 2026, 9:29 PM EDT. Biogen (NASDAQ: BIIB) shares rose 6% on Wednesday following its first-quarter 2026 earnings report. The biotech posted $2.48 billion in revenue, surpassing analyst expectations of $2.25 billion. Net income, excluding accounting standards (GAAP), increased 19% to over $529 million, or $3.57 per share, above forecasts of $2.95. Growth was driven by strong sales of Leqembi, for early Alzheimer's, up 74%, and the FDA-approved Skyclarys for Friedreich's ataxia. However, Biogen cut full-year adjusted net income guidance by $1 per share citing research and development charges. Revenue is expected to decline mid-single digits from 2025, excluding a pending $5.6 billion acquisition of Apellis Pharmaceuticals. Biogen's strategic shift towards high-potential therapies is underway despite cautious outlook.

Latest article

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

30 April 2026
Brookfield Renewable Corp’s NYSE shares fell 12.5% to $35.20 on Wednesday, with volume quadrupling the three-month average ahead of first-quarter results due Friday. The drop came despite a higher quarterly dividend and mixed analyst views. The company operates 47 GW of clean energy assets globally. Analysts expect a first-quarter loss of 33.92 cents per share on $1.62 billion in revenue.
Nu Holdings (NU) stock ticks up in premarket as Nubank heads into a key earnings window
Previous Story

Nu Holdings (NU) stock ticks up in premarket as Nubank heads into a key earnings window

Ondas Holdings (ONDS) stock jumps today after $10 million autonomous systems order haul
Next Story

Ondas Holdings (ONDS) stock jumps today after $10 million autonomous systems order haul

Go toTop